Odyssey Therapeutics
Odyssey Therapeutics: Innovating rapid, groundbreaking solutions in precision oncology and inflammation medicine.
- 175
- Company
- Boston, MA, USUnited States
Odyssey Therapeutics: Innovating rapid, groundbreaking solutions in precision oncology and inflammation medicine.
odysseytx.comCrawled Oct 16, 2026
The company’s pipeline focuses on immunology patients with significant unmet need and includes OD-07656 and other investigational therapies.
The article says Gary Glick followed a mentor’s advice to hire people with drug-development experience while building Odyssey.
Gary Glick raised more than $200 million to launch a company using medicinal chemistry to develop drugs for cancer and inflammatory diseases.
Odyssey Therapeutics completed an oversubscribed $218 million Series A round to advance programs in its pipeline and its discovery platform.
Odyssey Therapeutics launched with a $218 million Series A round, described as the year’s second-largest, to support work by nearly 100 employees, mostly recruited from big pharma firms.
The company says its team includes people from biotech, pharma, and academia.
The company is developing medicines that target disease pathology in autoimmune and inflammatory diseases.
The page provides contact information and addresses for the company’s Boston, Frankfurt, and Ann Arbor locations.
Odyssey is on a mission to transform the standard of care for patients affected by autoimmune and inflammatory conditions.
Odyssey Therapeutics’ privacy statement explains how the company collects, uses, and discloses personal information from its website and other websites that link to the policy.
Odyssey Therapeutics provides the website, whose use is subject to the terms and conditions in its Terms of Service agreement.
Odyssey Therapeutics reports Phase 2a results for OD-001, showing correlations between clinical efficacy and inflammatory biomarkers, mucosal transcriptomic signatures, and histologic disease activity. The findings reinforce the drug’s clinical proof of concept. OD-001 demonstrates a favorable tolerability profile and is administered orally, enhancing its potential as a therapeutic option.
Oct 2026Odyssey Therapeutics, IncNews article
Odyssey Therapeutics presents the design of a Phase 2a study evaluating its experimental drug **OD-001** in combination with **Vedolizumab** for autoimmune indications at the **ACG 2026** conference. The study aims to assess the safety and efficacy of the combination therapy. Topline induction results are anticipated in the second half of **2027**.
Oct 2026Odyssey Therapeutics, IncNews article
Odyssey Therapeutics presents additional Phase 2a clinical trial data for its experimental drug **OD-001** in treating ulcerative colitis at **UEG Week 2026**. The company highlights induction-phase findings as part of its ongoing development pipeline. Odyssey will also host a conference call and live webcast on **October 20, 2026**, to discuss the results with investors.
Oct 2026Odyssey Therapeutics, IncNews article
Odyssey Therapeutics announces Phase 2a monotherapy trial data for OD-001 accepted for presentation at United European Gastroenterology Week in October 2026. The company plans to begin Phase 2a combination trials of OD-001 with vedolizumab and Phase 2b monotherapy trials in the second half of 2026. As of June 30, 2026, Odyssey Therapeutics holds cash reserves to support ongoing operations.
Aug 2026Odyssey Therapeutics, IncNews article